RxDoctor Payments DataLook up a doctor →

Pramod Menon, MD

Interventional Cardiology · Covington, LANPI 1588620611

Payments from drug & device makers

$196,712in general payments, 2019–2025

Across 967 payments — averaging $203.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Research Institute, Inc.$104K
  • Novo Nordisk AS$21K
  • AstraZeneca$18K
  • Bayer$18K
  • Terumo Medical Corporation$12K
  • Edwards Lifesciences$4K
  • plus $20K from 54 others

What the payments were for

  • Consulting fees$10,52920%
  • Speaking & faculty fees$17,35032%
  • Travel & lodging$6371%
  • Food & beverage$25,03347%
  • Education$650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Kowa Research Institute, Inc.37$104,175
Novo Nordisk AS117$20,702
AstraZeneca29$18,378
Bayer14$18,283
Terumo Medical Corporation24$11,604
Edwards Lifesciences47$3,943
Medtronic(2 entities)100$3,851
Boston Scientific58$2,422
Abiomed28$2,307
Cardiovascular Systems Inc.15$1,031
Pfizer79$851
Abbott19$827
Merck36$685
Johnson & Johnson46$684
Amgen45$611
Novartis43$571
Novo Nordisk25$472
Kestra Medical Technology Services, Inc.15$354
Impulse Dynamics (USA) Inc.5$332
Philips North America LLC7$331
Sanofi-aventis U.S. LLC19$324
Amarin Pharma, Inc.19$323
E.r. Squibb & Sons, L.L.C.20$322
Z-medica, LLC5$308
Shockwave Medical, Inc4$258
Esperion Therapeutics, Inc.17$242
Angiodynamics, Inc.7$239
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)5$208
Surmodics, Inc.6$190
Kowa Pharmaceuticals America, Inc.11$168
Recor Medical Inc1$160
Inari Medical, Inc.1$146
Stryker1$141
Inspire Medical Systems, Inc.2$138
Tactile Systems Technology Inc9$136
Boehringer Ingelheim9$130
Regeneron Healthcare Solutions, Inc.5$96
Teleflex LLC2$93
Astellas Pharma US Inc5$85
Arbor Pharmaceuticals, Inc.3$59
Kiniksa Pharmaceuticals, Ltd.3$59
Penumbra, Inc.2$45
Atricure, Inc.1$42
Biotronik Inc.1$39
GSK2$36
Lilly USA, LLC2$34
Lundbeck LLC2$32
Irhythm Technologies, Inc.2$29
Acist Medical Systems, Inc.1$29
Cvrx, Inc.1$24
Itamar Medical Inc1$24
Kiniksa Pharmaceuticals International, PLC1$23
Baxter Healthcare1$21
Scpharmaceuticals Inc.1$19
Celonova Biosciences, Inc.1$18
Actelion Pharmaceuticals US, Inc.1$17
Catheter Precision, Inc. FKA Ra Medical Systems, Inc.1$15
Chiesi USA, Inc.1$14
Medicure Pharma Inc.1$10
Bardy Diagnostics, Inc.1$2

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$196,712 in reported general payments places this provider in the 90th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$624,795
Medicare patients
565
Services billed
8,578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban384$380,829
Repatha SureclickEvolocumab287$195,102
CamzyosMavacamten22$168,728
OzempicSemaglutide122$148,806
XareltoRivaroxaban141$126,709
FarxigaDapagliflozin Propanediol128$122,287
EntrestoSacubitril/Valsartan148$121,017
NexlizetBempedoic Acid/Ezetimibe69$62,283
MounjaroTirzepatide41$52,032
JardianceEmpagliflozin57$46,175
Praluent PenAlirocumab59$37,606
VascepaIcosapent Ethyl45$29,434
MultaqDronedarone Hcl23$25,469
NexletolBempedoic Acid29$25,112
WegovySemaglutide16$20,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$851$380,829384 claims
Novo NordiskOzempic, Wegovy$472$169,550138 claims
E.r. Squibb & Sons, L.L.C.Camzyos$322$168,72822 claims
AstraZenecaFarxiga, Brilinta$18,378$133,945146 claims
Johnson & JohnsonXarelto$684$126,709141 claims
NovartisEntresto$571$121,017148 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$242$87,39598 claims
Lilly USA, LLCMounjaro$34$52,03241 claims
Boehringer IngelheimJardiance$130$46,17557 claims
MerckVerquvo, Januvia$685$31,99739 claims
Sanofi-aventis U.S. LLCMultaq$324$25,46923 claims
Arbor Pharmaceuticals, Inc.Edarbi$59$15,77035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →